Levels of LRRK2 Ser935 cannot distinguish between healthy controls and PD patients basally or following LRRK2 kinase inhibitor treatment, limiting its use as a patient stratification biomarker17,18. This evidence concerns the gene LRRK2 and Parkinson disease.